ACON

Aclarion, Inc. Common Stock NASDAQ Listed Apr 22, 2022

Healthcare ·Services-Medical Laboratories · aclarion.com

$3.16

Pre-mkt $3.09 -1.93%

Mkt Cap $1.7M

usd

52w Low $2.34 8.5% of range 52w High $12.03

50d MA $3.26 200d MA $5.55

P/E (TTM) -0.2x

EV/EBITDA —

P/B 0.6x

Debt/Equity —

ROE -56.4%

P/FCF —

RSI (14) —

ATR (14) —

Beta —

50d MA $3.26

200d MA $5.55

Avg Volume —

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

SIC Code

8071

CIK (SEC)

1635077

Phone

833 275 2266

8181 ARISTA PLACE · BROOMFIELD, CO 80021

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 25, 2026	AMC	-3.60	-3.60	+0.0%	2.68	+0.0%	+0.0%	+2.2%	+4.4%	-6.3%	+15.7%	—
Nov 12, 2025	AMC	-2.64	-2.93	-11.0%	6.90	-3.2%	-10.9%	+0.2%	-2.3%	+1.5%	-3.9%	—
Aug 14, 2025	AMC	-2.26	-2.75	-21.7%	7.16	-1.5%	+2.2%	-0.5%	-3.6%	+0.4%	+3.1%	—
May 15, 2025	AMC	-1447.20	-9.32	+99.4%	6.90	+1.3%	+0.6%	+3.3%	-3.1%	-1.2%	+1.6%	—
Mar 27, 2025	AMC	-50.00	-1551.93	-3003.9%	14.09	-6.5%	-14.0%	-10.9%	+4.7%	+11.5%	-3.9%	—
Nov 14, 2024	AMC	-1621.62	-1351.35	+16.7%	153.68	-5.8%	-3.9%	+7.0%	+1.0%	-0.1%	+1.4%	—
Aug 14, 2024	AMC	-0.19	-1351.35	-9999.0%	188.14	-0.5%	+10.5%	-3.3%	+9.4%	-4.5%	-0.6%	—
May 15, 2024	AMC	-0.57	-3963.96	-9999.0%	251.45	+0.7%	+18.0%	-1.1%	+0.1%	-4.6%	+7.7%	—
Apr 2, 2024	AMC	-1.60	-13865.09	-9999.0%	302.99	-3.0%	-3.6%	-0.9%	+1.1%	-3.4%	-1.8%	—
Nov 14, 2023	AMC	-13024.80	-17297.30	-32.8%	49189.95	+3.0%	-7.3%	+11.1%	-21.4%	-3.3%	+11.8%	—
Aug 25, 2023	AMC	-0.09	-25945.95	-9999.0%	65108.88	+2.0%	+0.0%	-5.4%	+10.5%	+8.4%	-5.4%	—
Jul 3, 2023	AMC	-0.10	-0.15	-50.0%	102287.07	+6.1%	+1.2%	+2.0%	-5.5%	+2.9%	-2.4%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 25	Ascendiant Capital	Maintains	Buy → Buy	—	$3.45	$3.45	+0.0%	-6.4%	+1.5%	-6.7%	+0.7%	+6.2%
Nov 20	Ascendiant Capital	Maintains	Buy → Buy	—	$5.87	$6.21	+5.8%	+4.3%	-1.0%	+1.8%	-0.3%	+0.8%
Sep 19	Ascendiant Capital	Maintains	Buy → Buy	—	$8.20	$8.50	+3.7%	+14.6%	-5.4%	-9.4%	-4.3%	+4.3%
Dec 13	Maxim Group	Downgrade	Buy → Hold	—	$103.11	$104.00	+0.9%	-7.9%	+885.8%	-89.1%	+0.1%	+1.8%
Nov 27	Ascendiant Capital	Maintains	Buy → Buy	—	$163.89	$165.08	+0.7%	-2.2%	+1.6%	+0.0%	-0.6%	+0.4%
Aug 26	Ascendiant Capital	Maintains	Buy → Buy	—	$217.08	$215.27	-0.8%	+2.9%	-2.9%	-4.5%	-5.2%	-3.5%
Jul 6	Maxim Group	Maintains	Buy → Buy	—	$128148.48	$126918.36	-1.0%	-0.6%	-3.5%	-0.1%	-3.1%	+22.9%

Date	Insider	Title	Type	Shares	Price	Value	Owned After	D1%	D5%
May 12, 2026	Breidbart ScottDir	—	Buy	5,664	$3.18	$18K	5,664	—	—
May 11, 2026	Neal David KDir	—	Buy	2,500	$3.10	$8K	2,502	—	—
May 11, 2026	Ness BrentDir/Off	Chief Executive Officer	Buy	6,289	$3.18	$20K	6,300	+1.61%	—

Data updated apr 24, 2026 10:40am · Source: massive.com